MDS, also known as myelodysplasia or myelodysplastic syndromes , develops because the bone marrow cells do not develop into mature blood cells. Instead, these blood cells stay within the bone marrow in an immature state. There are many subtypes of MDS. Some cases are mild, while others are more severe, and carry a high risk of becoming acute myelogenous leukemia AML. The subtype you have, and the severity of your case, depend on many factors, including how low your blood counts are and any genetic changes you have in your bone marrow cells.
Studies suggest that 12, to 15, MDS cases are newly diagnosed annually in the U. The exact number of people living with MDS is unknown. To understand MDS, you must first learn how your bone marrow makes blood. This section defines the process and explains what goes wrong when you get MDS. We also recommend watching this video on our YouTube channel. Blood consists of blood cells floating in plasma. Plasma is mostly made of water. It also includes salts, proteins, hormones, minerals, vitamins and other nutrients and chemicals your body needs.
Increasing evidence suggests that the common mechanism governing this process is intramedullary apoptosis. Locally increased levels of tumor necrosis factor-alpha or Fas ligand may induce hematopoietic progenitors to "commit suicide" by altering the normal intracellular ratio of antiapoptotic and proapoptotic proteins. The N- ras oncogene can be mutated in myelodysplastic syndrome, albeit infrequently, but this alteration may be of biological and clinical significance. Patients with aplastic anemia are classified as having moderate, severe or very severe disease based on the number of lineages affected and the severity of the neutropenia see Table 1.
This classification is of prognostic significance for patients receiving medical therapy. The heterogeneity of myelodysplastic syndrome makes it a difficult disease to classify. The increasing availability of novel therapies for myelodysplastic syndrome requires accurate risk assessment for experimental subjects.
One recent approach to improving prognostication in such patients is the World Health Organization WHO classification of myelodysplastic syndrome. In addition, the 5q- syndrome was identified as a unique subset of refractory anemia with an excellent prognosis. The intermediate-risk group, refractory anemia with excess of blasts RAEB , was stratified into lower- and higher-risk groups based on the percentage of bone marrow blasts.
Chronic myelomonocytic leukemia CMML was reclassified as a myeloproliferative disorder that may or may not have associated dysplastic features. This proposal remains controversial and requires further validation. Many current clinical trials use this scoring system to establish enrollment criteria, or to stratify patients undergoing randomization. The newly diagnosed aplastic anemia patient should be expeditiously assessed for the appropriateness of allogeneic stem cell transplantation and, if this is a suitable option, referred to a transplant center for treatment.
Supportive care measures implemented prior to the transplant can significantly affect the outcome of the patient. Unless there is an actively life-threatening requirement for transfusion of blood products, they should be absolutely minimized to prevent sensitization of the patient to alloantigens and minimize the risk of graft rejection.
For the same reason, transfusion of blood products from family members must be prohibited. All blood products should be seronegative for cytomegalovirus CMV , leukocyte-reduced, and irradiated.
Leukocyte reduction decreases the risk of allosensitization and decreases the risk of CMV transmission. Irradiation of blood products prevents the proliferation of alloreactive T lymphocytes that could potentially induce transfusion-related graft-vs-host disease GVHD in the patient posttransplant.
Allogeneic stem cell transplantation is appropriate as initial therapy for younger patients with severe aplastic anemia. Retrospective comparisons of allogeneic bone marrow transplantation BMT and immunosuppressive therapy for severe aplastic anemia have demonstrated a survival benefit of early transplantation in younger patients, although reports differ over whether age should be less than 20 years [12] or less than 40 years.
Transplantation remains appropriate initial therapy for older patients, especially if very severe disease is present or if the patient has not received prior transfusions. An alternative strategy is to administer immunosuppressive therapy first and reserve transplantation for patients who do not respond to treatment.
The standard conditioning therapy prior to transplantation is cyclophosphamide Cytoxan, Neosar and antithymocyte globulin ATG [Atgam] for previously transfused patients, and cyclophosphamide alone for those who have not been transfused. Immunosuppression with ATG and cyclosporine Neoral, Sandimmune is well established as standard therapy for aplastic anemia. Concurrent treatment with both drugs is significantly more effective than use of either drug alone.
Renal function and transaminase levels should be monitored while patients are receiving cyclosporine and the drug dose should be adjusted if toxicity is observed.
Therapeutic options for aplastic anemia that does not respond to an initial course of immunosuppression include unrelated donor stem cell transplantation or a second course of ATG.
Because the survival following an unrelated transplant is best for patients who are transplanted within 1 year of diagnosis, the decision regarding this treatment is best made early. Prolonged cyclosporine administration as a single agent is occasionally effective. Hematopoietic growth factors, especially stem cell factor in combination with G-CSF, have induced trilineage responses in occasional refractory patients.
A retrospective analysis showed no significantly increased risk of clonal hematologic disorders myelodysplastic syndrome or AML associated with G-CSF given for a median of 6 months. The heterogeneous nature of myelodysplastic syndrome makes the selection of appropriate therapy a potentially confounding process.
The initial decision that should be made is whether a patient is an appropriate candidate for aggressive, potentially curative therapy, or instead should receive supportive care. Allogeneic stem cell transplantation is a potentially curative option for myelodysplastic syndrome, but this therapy has traditionally been reserved for younger patients, who comprise only a small fraction of myelodysplastic syndrome patients.
The selection of appropriate transplant candidates is complicated by the fact that low-risk patients, who could do well for several years with conservative management, have the best outcomes from transplantation, whereas high-risk patients do relatively poorly with each treatment strategy.
In an attempt to more successfully extend the use of allogeneic transplantation into older age groups, nonmyeloablative "mini" transplants have been performed for a variety of hematologic disorders. The intensity of the conditioning chemotherapy is reduced in an attempt to minimize toxicity and the risk of GVHD. The conditioning therapy is principally immunosuppressive, and is intended to permit the engraftment of donor hematopoietic and immunoregulatory cells but not to eliminate the malignancy.
Only a few myelodysplastic syndrome patients have been treated with this approach, but it will probably be best reserved for those at low risk, because the incidence of disease relapse for high-risk myelodysplastic syndrome will likely be higher with nonmyeloablative, compared to standard, conditioning therapy.
Autologous stem cell transplantation also is a potentially curable treatment for high-risk myelodysplastic syndrome. Following initial treatment with AML-type induction and consolidation chemotherapy, the autologous stem cells are collected. Standard high-dose conditioning therapy is then administered, followed by infusion of the autologous stem cells. The effectiveness of chemotherapy for myelodysplastic syndrome has been extensively evaluated at M. Anderson Cancer Center.
Standard induction doses of cytarabine were not studied. Patients received one to two induction cycles followed by repeated cycles of the same chemotherapy drugs at reduced doses every 4 to 6 weeks for 6 to 24 months. We will connect you to a cancer expert within one day. Please call for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call Click here for a current list of insurances accepted at Moffitt.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you. Moffitt Cancer Center is committed to the health and safety of our patients and their families. A secure website for patients to access their medical care at Moffitt.
In Myelodysplastic Syndrome MDS , there is impaired production of myeloid class of blood cells by the bone marrow whereas aplastic anemia is a condition in which the bone marrow is damaged leading to decreased new blood cell production. In MDS, the bone marrow produces new blood cells but they are abnormal and deformed whereas in aplastic anemia, the bone marrow stops producing new blood cells.
MDS commonly affects men above the age group of 60 yrs whereas aplastic anemia is commonly seen in teenagers and young adults. In aplastic anemia, our immune system attacks the healthy cells of the bone marrow and affects the production of new blood cells. Symptoms appear due to pancytopenia seen in both conditions. Pancytopenia is a decrease in red blood cells, white blood cells and platelets. Decreased red blood cells causes anemia.
Thus, patient develops symptoms like fatigue, weakness and breathlessness. Decreased white blood cells cause increased tendency to develop infections. Decreased platelets cause easy bruising and bleeding i.
Diagnosis is confirmed by blood investigations like a complete blood count. In MDS and aplastic anemia, it will show a decrease in haemoglobin, red blood cells, white blood cells and platelets. Bone marrow biopsy will help us to differentiate the two conditions.
0コメント